Amersham buys Sorin Diagnostics

Article

Radiopharmaceutical developer Amersham International in Decemberbought the radiopharmaceutical business and associated assets of Sorin Diagnosticsof Italy from parent Sorin Biomedica. Amersham, of Buckinghamshire,U.K., paid an initial consideration of

Radiopharmaceutical developer Amersham International in Decemberbought the radiopharmaceutical business and associated assets of Sorin Diagnosticsof Italy from parent Sorin Biomedica. Amersham, of Buckinghamshire,U.K., paid an initial consideration of Lit 22 billion ($13.9 million)in two installments, to be followed by payments ranging from Lit5 billion ($3.1 million) to Lit 28 billion ($17.6 million), dependingon sales results.

Amersham believes that the acquisition will boost its operationsin southern Europe. The company will combine its radiopharmaceuticalbusiness in Italy with Sorin's to form a new division known asAmersham Sorin Radiofarmaci. Sorin posted 1995 annual sales ofLit 33.7 billion ($21.2 million), with pretax profit of Lit 4.2billion ($2.6 million).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
CT-Based Deep Learning Model May Reduce False Positives with Indeterminate Lung Nodules by Nearly 40 Percent
Leading Breast Radiologists Discuss Rise of Breast Cancer Incidence in Women Under 40
New Research Examines Radiation Risks with CT Exposure Prior to Pregnancy
© 2025 MJH Life Sciences

All rights reserved.